Company Showcase

Company Showcase

NINDS SBIR graphic

The NINDS Small Business Program provides support to small businesses to develop products addressing unmet clinical and research needs.

Here we present company information about a small number of awardees ready to attract third-party collaborators and investors.

 

 

 

Afasci logo

AfaSci, Inc., developing novel non-opioid analgesics for chronic pain.
AfaSci Executive Summary (pdf, 269 kb)

AfaSci on NIH RePORTER

Axonis logo

AXONIS Therapeutics is advancing breakthrough drug discoveries to develop a pipeline of first-in-class neuron-reviving therapeutics for neurological disorders, to make a real difference for patients, their families, and the global healthcare system.
AXONIS Therapeutics Executive Summary (pdf, 193 kb)

AXONIS Therapeutics on NIH RePorter

Chemeleon logo

Chemeleon has created a platform technology for an instrument-free, in vitro diagnostic assay that provides a rapid, visible, colorimetric readout in minutes for the detection of cerebrospinal fluid leaks at the point-of-care that will be extended to an array of other markets and analytes (ex., viruses, proteins, drugs, etc.)

Chemeleon Executive Summary (pdf, 244 kb)

Chemeleon on NIH RePorter

Eysz Inc logo

Eysz Inc., is building a digital health platform for neurology - starting with Epilepsy - that will analyze eye-movement data to reliably quantitate seizures and neurocognitive symptoms to enable clinicians to deliver personalized medicine for their patients. 

Eysz Executive Summary (pdf, 1.04 Mb)

Eysz on NIH RePorter

Great Lakes Neurotechnologies logo

Great Lakes NeuroTechnologies, the leader in remote monitoring of movement disorders, markets KinesiaU™, enabling doctors to provide personalized, efficient, accurate therapy titration with fewer office visits, saving time and money.

Great Lakes Neurotechnologies Executive Summary (pdf, 268 kb)

Great Lakes Neurotechnologies on NIH RePorter

Neurexis Therapeutics logo

 

Neurexis Therapeutics, Neuroprotective Peptides for Cerebral Ischemia.

Neurexis Therapeutics Executive Summary (pdf, 1.21 Mb)

Neurexis Therapeutics on NIH RePorter

 

PathMakers Neurosciences Inc. logo

PathMaker Neurosystems is a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders including stroke and ALS. 

Pathmaker Neurosystems Executive Summary (pdf, 519 kb)

Pathmaker Neurosystems on NIH RePorter

Polycore Therapeutics logo

PolyCore Thereapeutics LLC is a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders.

PolyCore Therapeutics Executive Summary (pdf, 1.01 Mb)

PolyCore Therapeutics on NIH RePorter

Rebion logo

Rebion is commercializing a breakthrough diagnostic platform technology to definitively identify life-altering conditions that manifest from functional impairments in the brain, including lazy eye and traumatic brain injury.

Rebion Executive Summary (pdf, 576 kb)

Rebion on NIH RePORTER

Rumi Scientific logo

Rumi Scientific's platform makes it faster and more predictive to perform drug discovery in the CNS by identifying compounds which reverse the disease state at the cellular and tissue levels in large scale screenings, resulting in novel and better targets in the neurodegenerative and neurodevelopmental areas. 

Rumi Scientific Executive Summary (pdf, 168 kb)

Rumi Scientific on NIH RePorter

South Rampart Pharma logo

South Rampart Pharma is committed to improving the lives of people suffering from acute, neuropathic and chronic pain by developing a new class of non-opioid pain medicines that do not have the toxicities found in current over the counter and prescription medicines. 

South Rampart Pharma Executive Summary (pdf, 509 kb)

South Rampart Pharma on NIH RePorter

 

Tellus Therapeutics is a neonatal care company whose mission is to develop safe and effective treatments for newborns in the neonatal intensive care unit (NICU).  

Tellus Therapeutics Executive Summary (pdf, 263 kb)

Tellus Therapeutics on NIH RePorter